<p>根据 Janus Henderson Group PLC 最近向证券交易委员会提交的文件，该公司在 2023 年第四季度增持了 Catalyst Pharmaceuticals, Inc.（NASDAQ:CPRX - 免费报告）的股份，增幅为 32.2%。该基金在本季度额外购买了 115,832 股后，持有 476,023 股这家生物制药公司的股票。在最近的报告期结束时，Janus Henderson Group PLC 持有 Catalyst Pharmaceuticals 的股份占比为 0.40%，价值 9,935,000 美元。</p>
<ul>
<li>2 家生物科技公司凭借单一产品在市场上引起轰动</li>
</ul>
<p>其他一些机构投资者最近也买卖了 CPRX 的股票。Farther Finance Advisors LLC 在第四季度将其在 Catalyst Pharmaceuticals 的股份增加了 125.1%。Farther Finance Advisors LLC 现在持有 2,690 股这家生物制药公司的股票，价值 56,000 美元，此前在该期间额外购买了 1,495 股。Allspring Global Investments Holdings LLC 在第四季度将其在 Catalyst Pharmaceuticals 的股份增加了 13.9%。Allspring Global Investments Holdings LLC 现在持有 417,332 股这家生物制药公司的股票，价值 8,710,000 美元，此前在该期间额外收购了 50,888 股。Spire Wealth Management 在第四季度将其在 Catalyst Pharmaceuticals 的股份增加了 1,342.9%。Spire Wealth Management 现在持有 14,429 股这家生物制药公司的股票，价值 301,000 美元，此前在上个季度额外购买了 13,429 股。Sanctuary Advisors LLC 在第四季度将其在 Catalyst Pharmaceuticals 的股份增加了 91.5%。Sanctuary Advisors LLC 现在持有 59,447 股这家生物制药公司的股票，价值 1,241,000 美元，此前在上个季度额外购买了 28,407 股。最后，Nilsine Partners LLC 在第四季度收购了 Catalyst Pharmaceuticals 的新股份，价值 700,000 美元。79.22% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>分析师设定新目标价</h2>
<p>几家券商最近对 CPRX 进行了评估。StockNews.com 在 2 月 28 日的研究报告中将 Catalyst Pharmaceuticals 的股票评级从 “买入” 上调至 “强力买入”。HC Wainwright 在 2 月 28 日的研究报告中重申了 “买入” 评级，并设定了 35.00 美元的目标价。Stephens 在 2 月 27 日的研究报告中重申了 “增持” 评级，并设定了 33.00 美元的目标价。Baird R W 在 2 月 3 日的报告中将 Catalyst Pharmaceuticals 的评级上调至 “强力买入”。最后，Robert W. Baird 在 3 月 3 日的报告中将 Catalyst Pharmaceuticals 的目标价从 28.00 美元提高至 32.00 美元，并给予该公司 “跑赢大盘” 的评级。七位股票研究分析师对该股票给予了买入评级，两位给予了强力买入评级。根据 MarketBeat 的数据，Catalyst Pharmaceuticals 目前的共识评级为 “买入”，平均目标价为 32.29 美元。</p>
<ul>
<li>小型股 Catalyst Pharma 是市场上表现最佳的股票之一</li>
</ul>
<p><strong>查看我们对 CPRX 的最新分析</strong></p>
<h2>Catalyst Pharmaceuticals 的价格表现</h2>
<p>Catalyst Pharmaceuticals 的股票在周五开盘价为 24.37 美元。Catalyst Pharmaceuticals, Inc.的 12 个月低点为 14.75 美元，12 个月高点为 26.16 美元。该公司的 50 日简单移动平均线为 23.23 美元，200 日简单移动平均线为 22.47 美元。该股票的市值为 29.7 亿美元，市盈率为 20.65，市盈增长比率为 3.31，贝塔值为 0.70。</p>
<h2>Catalyst Pharmaceuticals 的内部交易</h2>
<p>在 Catalyst Pharmaceuticals 的其他新闻中，内部人士 Gary Ingenito 在 3 月 5 日的交易中出售了 44,904 股股票。该股票的平均售价为 22.09 美元，总价值为 991,929.36 美元。交易完成后，内部人士现在持有 68,873 股该公司的股票，价值约为 1,521,404.57 美元。这代表了他们持股比例的 39.47% 的下降。该交易已在 SEC 的法律文件中披露，可以通过此链接访问。此外，内部人士 Brian Elsbernd 在 3 月 3 日的交易中出售了 62,975 股股票。该股票的平均售价为 22.98 美元，总价值为 1,447,165.50 美元。交易完成后，内部人士现在持有 188,564 股该公司的股票，价值 4,333,200.72 美元。该交易使其持股比例下降了 25.04%。该销售的披露信息可以在这里找到。过去 90 天内，内部人士共出售了 351,879 股公司股票，价值 8,214,815 美元。当前 10.40% 的股票由内部人士持有。</p>
<h2>Catalyst Pharmaceuticals 公司简介</h2>
<p>（免费报告）</p>
<p>Catalyst Pharmaceuticals, Inc.是一家商业阶段的生物制药公司，专注于开发和商业化针对美国罕见的、严重的、慢性神经肌肉和神经疾病的治疗方案。它提供 Firdapse，一种用于治疗拉姆伯特 - 伊顿肌无力综合症（LEMS）患者的氨法普利磷酸盐片；以及 Ruzurgi，用于治疗儿童 LEMS 患者。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过 Catalyst Pharmaceuticals</li>
<li>如何计算通货膨胀率</li>
<li>Meta 的 AI 增长五大关键支柱——扎克伯格的大胆愿景</li>
<li>如何有效使用 MarketBeat 评级筛选器</li>
<li>零售投资者在 Rocket Lab 上大举下注——你也应该这样做吗？</li>
<li>我在哪里可以找到 52 周的高点和低点？</li>
<li>GE 航空：卡塔尔交易推动数十亿美元的增长引擎</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1BSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1BSWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Catalyst Pharmaceuticals 吗？</h2>
<p>在考虑 Catalyst Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Catalyst Pharmaceuticals 并不在名单上。</p>
<p>虽然 Catalyst Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

触媒制药公司

<p>Janus Henderson Group PLC 在第四季度将其在 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) 的持股增加了 32.2%，目前拥有 476,023 股，价值约 990 万美元。其他机构投资者也增加了他们的持股。分析师对 Catalyst Pharmaceuticals 的一致评级为 “买入”，平均目标价为 32.29 美元。该股票开盘价为 24.37 美元，12 个月的价格区间为 14.75 美元至 26.16 美元。最近的内部交易包括高管的大量股票出售</p>

<p>Janus Henderson Group PLC boosted its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 32.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 476,023 shares of the biopharmaceutical company's stock after buying an additional 115,832 shares during the quarter. Janus Henderson Group PLC owned 0.40% of Catalyst Pharmaceuticals worth $9,935,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>根据 Janus Henderson Group PLC 最近向证券交易委员会提交的文件，该公司在 2023 年第四季度增持了 Catalyst Pharmaceuticals, Inc.（NASDAQ:CPRX - 免费报告）的股份，增幅为 32.2%。该基金在本季度额外购买了 115,832 股后，持有 476,023 股这家生物制药公司的股票。在最近的报告期结束时，Janus Henderson Group PLC 持有 Catalyst Pharmaceuticals 的股份占比为 0.40%，价值 9,935,000 美元。</p>
</div><ul>
<li>2 Biotechs Making Waves With A Single Product in their Pipeline</li>
</ul>
<div class="lb-trans"><ul>
<li>2 家生物科技公司凭借单一产品在市场上引起轰动</li>
</ul>
</div><p>A number of other institutional investors also recently bought and sold shares of CPRX. Farther Finance Advisors LLC grew its stake in shares of Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after purchasing an additional 1,495 shares during the period. Allspring Global Investments Holdings LLC grew its stake in Catalyst Pharmaceuticals by 13.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 417,332 shares of the biopharmaceutical company's stock valued at $8,710,000 after acquiring an additional 50,888 shares during the period. Spire Wealth Management boosted its stake in Catalyst Pharmaceuticals by 1,342.9% during the 4th quarter. Spire Wealth Management now owns 14,429 shares of the biopharmaceutical company's stock worth $301,000 after purchasing an additional 13,429 shares during the last quarter. Sanctuary Advisors LLC boosted its stake in Catalyst Pharmaceuticals by 91.5% during the 4th quarter. Sanctuary Advisors LLC now owns 59,447 shares of the biopharmaceutical company's stock worth $1,241,000 after purchasing an additional 28,407 shares during the last quarter. Finally, Nilsine Partners LLC acquired a new stake in Catalyst Pharmaceuticals during the 4th quarter worth $700,000. 79.22% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些机构投资者最近也买卖了 CPRX 的股票。Farther Finance Advisors LLC 在第四季度将其在 Catalyst Pharmaceuticals 的股份增加了 125.1%。Farther Finance Advisors LLC 现在持有 2,690 股这家生物制药公司的股票，价值 56,000 美元，此前在该期间额外购买了 1,495 股。Allspring Global Investments Holdings LLC 在第四季度将其在 Catalyst Pharmaceuticals 的股份增加了 13.9%。Allspring Global Investments Holdings LLC 现在持有 417,332 股这家生物制药公司的股票，价值 8,710,000 美元，此前在该期间额外收购了 50,888 股。Spire Wealth Management 在第四季度将其在 Catalyst Pharmaceuticals 的股份增加了 1,342.9%。Spire Wealth Management 现在持有 14,429 股这家生物制药公司的股票，价值 301,000 美元，此前在上个季度额外购买了 13,429 股。Sanctuary Advisors LLC 在第四季度将其在 Catalyst Pharmaceuticals 的股份增加了 91.5%。Sanctuary Advisors LLC 现在持有 59,447 股这家生物制药公司的股票，价值 1,241,000 美元，此前在上个季度额外购买了 28,407 股。最后，Nilsine Partners LLC 在第四季度收购了 Catalyst Pharmaceuticals 的新股份，价值 700,000 美元。79.22% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several brokerages have recently weighed in on CPRX. StockNews.com raised shares of Catalyst Pharmaceuticals from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Friday, February 28th. HC Wainwright reissued a &#34;buy&#34; rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Stephens reissued an &#34;overweight&#34; rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Baird R W raised Catalyst Pharmaceuticals to a &#34;strong-buy&#34; rating in a report on Monday, February 3rd. Finally, Robert W. Baird increased their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an &#34;outperform&#34; rating in a report on Monday, March 3rd. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Catalyst Pharmaceuticals presently has a consensus rating of &#34;Buy&#34; and an average target price of $32.29.</p>
<div class="lb-trans"><p>几家券商最近对 CPRX 进行了评估。StockNews.com 在 2 月 28 日的研究报告中将 Catalyst Pharmaceuticals 的股票评级从 “买入” 上调至 “强力买入”。HC Wainwright 在 2 月 28 日的研究报告中重申了 “买入” 评级，并设定了 35.00 美元的目标价。Stephens 在 2 月 27 日的研究报告中重申了 “增持” 评级，并设定了 33.00 美元的目标价。Baird R W 在 2 月 3 日的报告中将 Catalyst Pharmaceuticals 的评级上调至 “强力买入”。最后，Robert W. Baird 在 3 月 3 日的报告中将 Catalyst Pharmaceuticals 的目标价从 28.00 美元提高至 32.00 美元，并给予该公司 “跑赢大盘” 的评级。七位股票研究分析师对该股票给予了买入评级，两位给予了强力买入评级。根据 MarketBeat 的数据，Catalyst Pharmaceuticals 目前的共识评级为 “买入”，平均目标价为 32.29 美元。</p>
</div><ul>
<li>Small-Cap Catalyst Pharma Is Among Market's Best Price Performers</li>
</ul>
<div class="lb-trans"><ul>
<li>小型股 Catalyst Pharma 是市场上表现最佳的股票之一</li>
</ul>
</div><p><strong>View Our Latest Analysis on CPRX</strong></p>
<div class="lb-trans"><p><strong>查看我们对 CPRX 的最新分析</strong></p>
</div><h2>Catalyst Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Catalyst Pharmaceuticals 的价格表现</h2>
</div><p>Catalyst Pharmaceuticals stock opened at $24.37 on Friday. Catalyst Pharmaceuticals, Inc. has a 12 month low of $14.75 and a 12 month high of $26.16. The business has a 50 day simple moving average of $23.23 and a 200-day simple moving average of $22.47. The stock has a market capitalization of $2.97 billion, a PE ratio of 20.65, a price-to-earnings-growth ratio of 3.31 and a beta of 0.70.</p>
<div class="lb-trans"><p>Catalyst Pharmaceuticals 的股票在周五开盘价为 24.37 美元。Catalyst Pharmaceuticals, Inc.的 12 个月低点为 14.75 美元，12 个月高点为 26.16 美元。该公司的 50 日简单移动平均线为 23.23 美元，200 日简单移动平均线为 22.47 美元。该股票的市值为 29.7 亿美元，市盈率为 20.65，市盈增长比率为 3.31，贝塔值为 0.70。</p>
</div><h2>Insider Transactions at Catalyst Pharmaceuticals</h2>
<div class="lb-trans"><h2>Catalyst Pharmaceuticals 的内部交易</h2>
</div><p>In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. This represents a 39.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Brian Elsbernd sold 62,975 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the transaction, the insider now owns 188,564 shares of the company's stock, valued at $4,333,200.72. The trade was a 25.04% decrease in their position. The disclosure for this sale can be found here. Insiders sold 351,879 shares of company stock worth $8,214,815 over the last 90 days. 10.40% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在 Catalyst Pharmaceuticals 的其他新闻中，内部人士 Gary Ingenito 在 3 月 5 日的交易中出售了 44,904 股股票。该股票的平均售价为 22.09 美元，总价值为 991,929.36 美元。交易完成后，内部人士现在持有 68,873 股该公司的股票，价值约为 1,521,404.57 美元。这代表了他们持股比例的 39.47% 的下降。该交易已在 SEC 的法律文件中披露，可以通过此链接访问。此外，内部人士 Brian Elsbernd 在 3 月 3 日的交易中出售了 62,975 股股票。该股票的平均售价为 22.98 美元，总价值为 1,447,165.50 美元。交易完成后，内部人士现在持有 188,564 股该公司的股票，价值 4,333,200.72 美元。该交易使其持股比例下降了 25.04%。该销售的披露信息可以在这里找到。过去 90 天内，内部人士共出售了 351,879 股公司股票，价值 8,214,815 美元。当前 10.40% 的股票由内部人士持有。</p>
</div><h2>Catalyst Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Catalyst Pharmaceuticals 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.</p>
<div class="lb-trans"><p>Catalyst Pharmaceuticals, Inc.是一家商业阶段的生物制药公司，专注于开发和商业化针对美国罕见的、严重的、慢性神经肌肉和神经疾病的治疗方案。它提供 Firdapse，一种用于治疗拉姆伯特 - 伊顿肌无力综合症（LEMS）患者的氨法普利磷酸盐片；以及 Ruzurgi，用于治疗儿童 LEMS 患者。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Catalyst Pharmaceuticals</li>
<li>How to Calculate Inflation Rate</li>
<li>Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision</li>
<li>How to Effectively Use the MarketBeat Ratings Screener</li>
<li>Retail Investors Are Betting Big on Rocket Lab—Should You Too?</li>
<li>Where Do I Find 52-Week Highs and Lows?</li>
<li>GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Catalyst Pharmaceuticals</li>
<li>如何计算通货膨胀率</li>
<li>Meta 的 AI 增长五大关键支柱——扎克伯格的大胆愿景</li>
<li>如何有效使用 MarketBeat 评级筛选器</li>
<li>零售投资者在 Rocket Lab 上大举下注——你也应该这样做吗？</li>
<li>我在哪里可以找到 52 周的高点和低点？</li>
<li>GE 航空：卡塔尔交易推动数十亿美元的增长引擎</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1BSWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CPRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Catalyst Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Catalyst Pharmaceuticals 吗？</h2>
</div><p>Before you consider Catalyst Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Catalyst Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalyst Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Catalyst Pharmaceuticals 并不在名单上。</p>
</div><p>While Catalyst Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Catalyst Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Janus Henderson 集团 PLC 增加了其在触媒制药公司（NASDAQ:CPRX）的股份